168 related articles for article (PubMed ID: 20153190)
1. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
Zhou G; Wu D; Hermel E; Balogh E; Gochin M
Bioorg Med Chem Lett; 2010 Mar; 20(5):1500-3. PubMed ID: 20153190
[TBL] [Abstract][Full Text] [Related]
2. Computer-aided design, synthesis, and biological activity evaluation of potent fusion inhibitors targeting HIV-1 gp41.
Tan JJ; Zhang B; Cong XJ; Yang LF; Liu B; Kong R; Kui ZY; Wang CX; Hu LM
Med Chem; 2011 Jul; 7(4):309-16. PubMed ID: 21568877
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of indole-based compounds as small molecule HIV-1 fusion inhibitors targeting glycoprotein 41.
Zhou G; Sofiyev V; Kaur H; Snyder BA; Mankowski MK; Hogan PA; Ptak RG; Gochin M
J Med Chem; 2014 Jun; 57(12):5270-81. PubMed ID: 24856833
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
Wang Y; Lu H; Zhu Q; Jiang S; Liao Y
Bioorg Med Chem Lett; 2010 Jan; 20(1):189-92. PubMed ID: 19932616
[TBL] [Abstract][Full Text] [Related]
5. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.
Zhou G; Wu D; Snyder B; Ptak RG; Kaur H; Gochin M
J Med Chem; 2011 Oct; 54(20):7220-31. PubMed ID: 21928824
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors.
Zhou G; Chu S; Nemati A; Huang C; Snyder BA; Ptak RG; Gochin M
Eur J Med Chem; 2019 Jan; 161():533-542. PubMed ID: 30390441
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Jiang S; Tala SR; Lu H; Zou P; Avan I; Ibrahim TS; Abo-Dya NE; Abdelmajeid A; Debnath AK; Katritzky AR
Bioorg Med Chem Lett; 2011 Nov; 21(22):6895-8. PubMed ID: 21978673
[TBL] [Abstract][Full Text] [Related]
8. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
He XY; Lu L; Qiu J; Zou P; Yu F; Jiang XK; Li L; Jiang S; Liu S; Xie L
Bioorg Med Chem; 2013 Dec; 21(23):7539-48. PubMed ID: 23673219
[TBL] [Abstract][Full Text] [Related]
9. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
10. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
Nomura W; Hashimoto C; Ohya A; Miyauchi K; Urano E; Tanaka T; Narumi T; Nakahara T; Komano JA; Yamamoto N; Tamamura H
ChemMedChem; 2012 Feb; 7(2):205-8. PubMed ID: 22247043
[No Abstract] [Full Text] [Related]
11. A targeted covalent small molecule inhibitor of HIV-1 fusion.
Zhou G; He L; Li KH; Pedroso CCS; Gochin M
Chem Commun (Camb); 2021 May; 57(37):4528-4531. PubMed ID: 33956029
[TBL] [Abstract][Full Text] [Related]
12. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation.
Liu B; Joseph RW; Dorsey BD; Schiksnis RA; Northrop K; Bukhtiyarova M; Springman EB
Bioorg Med Chem Lett; 2009 Oct; 19(19):5693-7. PubMed ID: 19699090
[TBL] [Abstract][Full Text] [Related]
14. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of HIV-1 attachment. Part 3: A preliminary survey of the effect of structural variation of the benzamide moiety on antiviral activity.
Meanwell NA; Wallace OB; Wang H; Deshpande M; Pearce BC; Trehan A; Yeung KS; Qiu Z; Wright JJ; Robinson BA; Gong YF; Wang HG; Spicer TP; Blair WS; Shi PY; Lin PF
Bioorg Med Chem Lett; 2009 Sep; 19(17):5136-9. PubMed ID: 19632112
[TBL] [Abstract][Full Text] [Related]
16. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L; Gochin M; Liu K
Curr Top Med Chem; 2011 Dec; 11(24):2959-84. PubMed ID: 22044229
[TBL] [Abstract][Full Text] [Related]
17. Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection.
Huhmann S; Nyakatura EK; Rohrhofer A; Moschner J; Schmidt B; Eichler J; Roth C; Koksch B
Chembiochem; 2021 Dec; 22(24):3443-3451. PubMed ID: 34605595
[TBL] [Abstract][Full Text] [Related]
18. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors.
Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K
Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
Yang J; Li LL; Li JR; Yang JX; Zhang F; Chen G; Yu R; Ouyang WJ; Wu SW
Bioorg Med Chem Lett; 2018 Jan; 28(1):49-52. PubMed ID: 29162455
[TBL] [Abstract][Full Text] [Related]
20. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation.
Sepehri S; Saghaie L; Fassihi A
Mol Inform; 2017 Mar; 36(3):. PubMed ID: 27730744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
